(A) Number of CALB1+ cells at P30 (One-way ANOVA, F(2,16)=9.464, p=0.002, n ≥ 6). (B) Number of BrdU+ PCs 2 days post DT-injection in P1- or P5-PC-DTR mice (Two-tailed t-test, p=0.04). (C). Quantification of CB area in midline sagittal sections demonstrates that CB size is smaller at P12 in P5-PC-DTR mice but not later (Two-way ANOVA, F(1,22)=7.045, p=0.01, n ≥ 3). (D–E) PC soma size (D, One-way ANOVA, F(2.11) = 20.56, p=0.0002, n ≥ 4) and primary and secondary dendrite lengths (E, One-way ANOVA, F(2,11)=14.54, p=0.0008, n ≥ 4) at P30 were increased in P5-PC-DTR animals compared to No DT and P1-PC-DTR animals. (F–G) Latency to fall from rotarod at each trial (F, Two-way ANOVA, F(2,34)=8.37, p=0.001, n ≥ 9) and cumulative analysis (G, One-way ANOVA, F(2,34)=11.12, p=0.0002, n ≥ 9, No DT vs. DT@P1: p=0.83) for P30 P5-PC-DTR animals compared to No DT and P1-PC-DTR animals. (H) Analysis of grip strength showed no change in P1 (n = 9, vs No DT: p=0.89) and P5 (n = 11, vs. No DT: p=0.84, vs. DT@P1: p=0.64) DT-injected mice compared to controls (No DT, n = 17). (I–J) Representative images (I) and quantification (J) of footprint analysis performed on P1- (vs. No DT: stride: p=0.10 and sway: p=0.90) and P5-PC-DTR mice and controls (Two-way ANOVA, F(2,133)=73.45, p=0.0001, n ≥ 9). Significant post hoc comparisons are shown.